Material and Method: The study included 20 benign prostatic hyperplasia, 8 high-grade prostatic intraepithelial neoplasia and 82 prostatic carcinoma patients. Immunohistochemistry was performed on sections obtained from materials of suprapubic prostatectomy, tru-cut biopsy, transurethral resection and radical prostatectomy. While Fas and FasL were evaluated in glandular and stromal areas, DcR1 and FLIP were evaluated in only glandular areas. Intensity and extent of immunostaining for Fas and FasL antibodies were separately scored and both scores were summarized. The total score of ≥ 4 both for Fas and FasL, expressions of FLIP and DcR1determined in more than 5% of glandular areas were accepted as positive.

Results: Glandular FasL positivity was observed in 63.8 and 20% of the cases with prostatic carcinoma and benign prostatic hyperplasia, respectively (p=0.001). The loss of stromal Fas expression in PCa was obvious (p<0.001). FLIP positivity was more frequently seen in high-grade prostatic intraepithelial neoplasia and PCa.

Conclusion: In prostatic carcinoma, decreased stromal Fas expression, contrary to higher glandular FasL positivity, supports the assertion that sensitivity of epithelial and stromal cells to apoptosis and their protective pathways against apoptosis undergo alterations. Increased FLIP expressions in high-grade prostatic intraepithelial neoplasia and prostatic carcinoma can also be interpreted accordingly.

Fas (CD95, Apo-1) is a type 1membrane receptor of the tumor necrosis factor/nerve growth factor receptor super family. FasL (Fas ligand) is a natural ligand for Fas and a type II transmembrane protein. Fas and FasL complex induces apoptosis in target cells. A variety of cells express Fas. Some of these cells are activated lymphocytes and natural killer cells. Fas and FasL have also been detected in malignant neoplasms, including melanoma, colon carcinoma, renal cell carcinoma, astrocytoma, esophageal carcinoma, and breast carcinoma. The up-regulation of FasL in malignant cells may play a role in escaping immune surveillance by inducing apoptosis of activated lymphocytes and natural killer cells. It has been shown that FasL is secreted constitutively by prostate carcinoma cells in vitro. Dysregulation of Fas and FasL homeostasis may play a role in the development and progression of prostate carcinoma^1-5. Another receptor family involved in the extrinsic apoptotic pathway is tumor necrosis factor-related apoptosis-inducing ligand (TRA IL) and its receptors (TRA IL-R). TRA IL is an analogue of FasL. TRA IL is expressed on the surface of many normal cells, and up to five types of TRA IL-R have been described. Among them, TRA IL-R1 (DR4) and TRA IL-R2 (DR5) contain a cytoplasmic death region and transmit apoptotic signals. TRA IL-R3 (DcR1) and TRA IL-R4 (DcR2) block intracellular transmission of signals and hence they are called “decoy receptors”^6-8. FLIP (FLICE inhibitor protein) is a protein with amino acid sequences similar to caspase-8 and capsase-10. FLIP competes with them for binding to FADD (Fas associated death domain) and inhibits Fas-mediated apoptosis at the subreceptor level⁹. Some reports are available on FLIP expression in prostate cancers¹⁰.

In this study, our aim was to reveal the probable alterations in extrinsic apoptotic mechanisms in prostatic cancer tissues.

Immunohistochemistry
Immunohistochemical analyses were performed on paraffin sections 4 μm thick. Characteristics of primary antibodies used in the analysis are shown in Table I. The sections were boiled in citrate buffer solution (pH=6) for the epitope retrieval process. Immunohistochemical evaluation for all antibodies was performed on areas that demonstrated the most optimal immunostaining. Cytoplasmic and membranous staining for both glandular and stromal cells was considered as significant (Figure 1A-D). Intensity and extent of immunostaining for Fas and FasL antibodies were separately scored according to the following scheme (Table II). Both scores were summarized and cases with a total score of ≥ 4 both for Fas and FasL were accepted as positive. Since HGPIN is a stroma-free lesion, stromal expressions for Fas and FasL were not evaluated in this group. In analyses of FLIP and DcR1, cytoplasmic staining of glandular epithelial cells was considered to be significant and immunostaining for these two antibodies in more than 5% of glandular areas was accepted as positive. Tonsil tissue was used as the positive control tissue for all antibodies and phosphate buffer solution (PBS) instead of primary antibody as the negative control in the incubation period.

Click Here to Zoom

Table I: Primary antibodies.

Click Here to Zoom

Table II: The semiquantitative grading scheme used for analysis of Fas and FasL immunostaining.

Click Here to Zoom

Figure 1: A) Glandular and stromal Fas expressions in BPH (Fas; x20). B) Glandular FasL expression in PCa (FasL; x10). C) Membranous DcR1 expressions in PCa (DcR1; x30). D) FLIP expression in PCa (FLIP; x30).

Statistical Analysis
One-way-ANOVA for age was performed while categorized variables were analyzed by chi-square. Fisher’s exact test was used if the number of cells with expected frequencies less than five did not exceed 20% of all cells. The independent samples t-test was used for comparison of the mean age between the groups. A p value ≤0.05 was accepted as significant.

Fas Analysis
Glandular Fas expression was not seen in cases of HGPIN while groups of BPH and PCa showed glandular Fas expressions at rates of 20% and 9.8%, respectively. Although a statistical significant difference for glandular Fas expression between the groups could not be demonstrated, the BHP group showed a higher rate of glandular Fas expression than those of other groups (p=0.340) (Table III, Figure 2).

Click Here to Zoom

Table III: The distribution of positivity rates for the apoptosis related antibodies according to the study groups.

Click Here to Zoom

Figure 2: Fas and FasL expression rates by groups.

Stromal Fas expression showed a significant difference between BPH and PCa. Stromal Fas expression was detected in 45% (9 cases) of the cases in the BPH group while the positivity rate was 1.2% (1 case) in the PCa group. Stromal Fas expression had statistical significance in our study (p<0.001) (Table III, Figure 2).

Glandular Fas expression was only seen in 8 cases (9.8%). The rates of glandular Fas expression were similar in the DPCa, MDPCa and PDPCa groups (11.5%, 8.3% and 9.4%, respectively) (p=0.999) (Table IV, Figure 3).

Click Here to Zoom

Table IV: The distribution of positivity rates for the apoptosis related antibodies according to the total Gleason scores in PCa group.

Click Here to Zoom

Figure 3: Fas and FasL expression rates according to the Gleason grades in PCa group.

Stromal Fas expression was noted in only one case (1.2%) in the PCa group (p=0.296).

FasL Analysis
Glandular FasL expression could not be evaluated in 2 cases in the PCa group because of technical reasons. Glandular FasL expression showed a statistically significant difference between the groups. Eighty percent of the cases of BPH were negative for FasL. The rates of positivity in HGPIN and PCa were 62.5 and 63.8%, respectively. The difference for FasL expression between BPH and the groups representing neoplastic transformation (HGPIN and PCa) was statistically significant (p=0.001) (Table III, Figure 2).

Stromal FasL expression did not show a significant difference between BPH and PCa. Stromal FasL expression was seen in 28.8% of PCa cases while the other groups showed stromal FasL expression at rates of 50%, approximately (Table III, Figure 2).

Glandular FasL expression was detected in 51 (63.8%) of 80 cases in the PCa group. A significant intergroup difference for glandular FasL expression was not seen between groups as categorized by Gleason scores (p=0.541). The rates of glandular FasL positivity in DPCa, MDPCa and PDPCa were 60%, 58.3% and 71%, respectively (Table IV, Figure 3).

Stromal FasL positivity in the PCa group was determined in 23 cases (28.8%). Stromal FasL positivity rates in each subgroup categorized by total Gleason scores were close to each other (p=0.641) (Table IV, Figure 3).

DcR1 Analysis
There was no difference for DcR1expression between the groups (p=0.999). The highest rate for DcR1 positivity was 10% among all groups. Stromal and nuclear expressions of DcR1 were not seen in any group (Table III, Figure 4).

Click Here to Zoom

Figure 4: FLIP and DcR1 expression rates by the groups.

The DcR1 positivity rate was 9.8% (8 cases) in the PCa group. 3.8% of DPCa cases were positive for DcR1, while 15.6% of PDPCa cases showed DcR1 positivity (p=0.329). DcR1 positivity was 8.3% in the MDPCa group (Table IV, Figure 5).

Click Here to Zoom

Figure 5: FLIP and DcR1 expression rates according to the Gleason grades in the PCa group.

FLIP Analysis
FLIP expression could be evaluated in only 80 cases in the PCa group. Two cases were excluded due to technical reasons. Only 5% of the cases in the BPH group showed positivity for FLIP while the rates of FLIP positivity in the HGPIN and PCa groups were 37.5% and 18.8%, respectively (p=0.102). Stromal and nuclear positivity for FLIP was not seen in any case (Table III, Figure 4).

Fifteen cases (18.8%) were positive for FLIP in the PCa group. FLIP positivity according to Gleason grade did not show a significant intergroup difference (p=0.262) (Table IV, Figure 5).

In our study, we also evaluated Fas expression by stromal cells. Relative to cases with BPH (45%), a marked loss of stromal Fas expression was seen in the PCa group (1.2 %) (p<0.001). Recently, the role of stromal cells in carcinogenesis has been more clearly understood and many researchers have drawn the attention to the role of stromal cells in prostate carcinogenesis and especially their impact on promoting tumoral invasiveness¹⁵. Increased vulnerability of stromal cells to destructive processes facilitates tumoral invasion. Therefore, an increase in Fas expression by stromal cells can also facilitate tumoral invasion. However, our results seem to contradict these findings. In any event, some data related to prostate carcinogenesis have indicated that loss of stromal Fas expression might have a role in prostate carcinogenesis. Microarray profiles of stromal tissue samples of the prostate glands of the elderly have demonstrated the presence of dysregulations related to some factors derived from stromal cells^16,17. Alterations in membrane-bound molecules of stromal cells and their secreted molecules can exert important effects on malignant transformation^16-18. Loss of stromal Fas confers resistance on stromal cells at least for a while against apoptosis and may maintain some functions that will contribute to tumoral progression. Other probable mechanisms related to development of resistance to the apoptotic process despite increased Fas expression in tumoral cells are as follows: production of soluble Fas which neutralizes FasL, overexpression of bcl-2, overexpression of Fas-associated phosphatase 1 which interacts with the suppressive component of Fas, overexpression of FLIP which inhibits Fas-associated apoptosis and mutations in the primary structure of Fas, caspase-8 and caspase-10^2,19-28. From these outcomes one can infer that largerscale studies should be performed to reveal the state of Fas expression in benign and malignant prostatic lesions.

In a study by Jiang et al., Fas and FasL expressions were analyzed. FasL expression demonstrated marked increases in benign prostate, HGPIN and prostate cancer tissue when compared with Fas expression⁵. FasL expression rates in HGPIN and malignant prostate tissues were 92 and 97 %, respectively and conspicuously higher relative to benign prostate tissues (49%)⁵. Overexpression of FasL in tumor cells can protect tumor cells against the effects of cytotoxic T-lymphocytes and natural killer cells. Results of some in vitro cell culture studies support the above mentioned assertion^1,29,30. In our study, glandular FasL expression demonstrated significant differences between malignant and benign cases (p=0.001). Glandular FasL expression was detected in cases with BPH (20%), HGPIN (62.5 %) and PCa (63.8%) in respective percentages. According to our results, increased FasL expression can be evaluated as a sign of prostate carcinogenesis starting from the HGPIN stage.

In our study, though a significant difference was not detected between groups as for stromal FasL expression, higher loss of stromal FasL expression in the PCa group relative to the BPH group was a remarkable finding. Younger cases of BPH showed significantly more expression of stromal FasL than the older cases, in our study (p=0.016). In the PCa group, an increase in glandular FasL expression despite loss of stromal FasL expression can be meaningful in that this condition facilitates the invasion/infiltration process.

Intragroup analysis in the PCa group according to Gleason grade categories with respect to Fas and FasL expressions did not demonstrate a significant difference regarding glandular and stromal expressions, which indicates the presence of a homogenicity for expressions of Fas and FasL in the PCa group.

The idea of treatment with activation of apoptosis via these receptors whose presence has been demonstrated in vitro in prostate cancer cell strains has been evaluated as an attractive treatment modality (6-8). Since, TNF-α and FasL, have more toxic side effects than TRA IL, TRA IL is thought to be a safer and more reliable therapeutic agent³¹. On the other hand, nearly 60% of malignancies seen in human beings are resistant to TRA IL^32,33. Though the mechanism of this resistance is not known for sure, this resistance was suggested to occur by containment of decoy receptors in normal cells in competition with death receptors³⁴ or the presence of apoptosis-inhibitor molecules like FLIP^24,35.

Outcomes of the study investigating the correlations between TRA IL profile and resistance to TRA IL^36,37 have indicated that expression of the DcR2 receptor absolutely resulted in resistance to TRA IL despite the presence of death receptors. Conversely, lack of expression of decoy receptors in cancer cells was associated with TRA IL sensitivity. Sanlioglu et al. demonstrated the presence of death and decoy receptors in both benign and malignant prostate tissues³⁸. These receptors were specific to epithelial cells and they were not observed in stromal cells. DcR2 receptors were expressed in increasing amounts both in malignant and benign groups. However, expressions of both TRA IL and its receptors demonstrated a marked increase in prostate cancer. Expression profiles of both TRA IL and TRA IL-R may have a critical value in the discrimination between benign and malignant tissues and also in the TRA IL-mediated gene therapy³⁸. Increased DcR2 receptor expression may complicate this treatment approach^36,37. Ionizing radiation and classical chemotherapeutic agents reinforce TRA ILinduced apoptosis^39-41. Therefore in prostate cancers with increased DcR2 receptor expression, treatment with ionizing radiation and chemotherapeutics might be useful so as to overcome resistance to TRA IL³⁸. Anees et al. reported that expression of TRA IL increased in the tumoral parenchyma, while it got lost in the stromal tissue¹⁸. They observed that significant absence of TRA IL expression in prostate cancer was associated with life-expectancy. High grade prostate cancers exhibit more severe stromal cell proliferation⁴². Changes in the composition of stromal cells may also indicate alterations in the interactions between stroma and parenchyma. Anees et al. reported that loss of expression of TRA IL in stromal tissue is an independent parameter effective on the expectation of disease-free life¹⁸. It has been suggested that alterations emerging in stromal environment with age may accelerate the process of prostate carcinogenesis^43,44. Anees et al. asserted a tumor suppressive role of stromal TRA IL expression in prostate carcinogenesis¹⁸. Anees et al. explained their hypothesis by a decrease in stromal TRA IL levels during the course of malignant transformation and the presence of a direct correlation between stromal TRA IL expression and disease-free life-span¹⁸. Anees et al. reported higher FLIP levels in prostate cancer patients. It has been speculated that over-expression of FLIP can exert a clear-cut impact on the inhibition of apoptosis despite increased death receptor and TRA IL levels while conversely, a decrease in death receptors may result in net decreases in apoptotic activity irrespective of lower levels of FLIP expression¹⁸. Anees et al. concluded that the loss of death receptor was associated with higher Gleason score and advanced age (≥ 60 years). Although decrease in TRA IL-mediated apoptosis with advanced age and higher Gleason scores is accompanied by a decrease in FLIP expression, a decrease in death receptors is the determinative factor. It has been suggested that loss of stromal TRA IL expression is seen in malignant transformation, which is also strongly correlated with an unfavorable prognosis¹⁸.

In our study, DcR1 expression was not seen in the HGPIN group while in other groups DcR1 expression was very close to each other. Though any intra-group significant difference did not emerge in the PCa group, DcR1 expression in the DPCa, MDPCa and PDPCa groups was seen at a rate of 3.8 %, 8.3% and 15.6%, respectively (P=0.329). According to our study, rates of DcR1 positivity increase contrary to decrease in the degree differentiation in prostatic adenocarcinoma. This result may demonstrate -though partially- the potential impact of DcR1 on the progression of prostate cancer. In our study, stromal DcR1 expression was not seen in any of the cases.

Increased FLIP expression has been reported in from metastatic prostate cancer foci rather than primary foci⁴⁵. Increased FLIP expression has been also demonstrated in other malignant neoplasms relative to normal tissues^21-24. Kim et al. reported that cytoplasmic and nuclear FLIP expression was seen in nearly all of the benign and malignant prostatic tissue samples, without any difference between benign and malignant tissue samples⁴. In our study FLIP positivity was more frequently seen in the HGPIN and PCa groups when compared with the BPH group (37.5, %18.8 and 5 %, respectively) although the difference was statistically insignificant (P=0.102). This finding of ours indicates that the inhibition of apoptosis has a role in malignant transformation. No intra-group difference was observed in the PCa group as for FLIP expression, and the PCa group can be said to demonstrate homogenous FLIP expression as is the case with Fas and FasL expressions.

We have noticed that different scoring systems are used in various studies in the literature. Our scoring system was modified from some of these scoring systems. Jiang et al. scored their immunoexpressions according to staining intensity and extensity. Weak, unequivocal-moderate and strong intensities were scored as 1, 2 and 3, respectively, while extensity was evaluated from 5% to 100%. Statistical analysis was performed on the basis of this scoring system. They did not use a cut-off value for positivity⁵. Şanlıoğlu et al. scored both of intensity and distribution of immunostaining in their study. Their scoring system was as follows; 0; negative, 1; weak, 2; moderate, 3; strong staining for intensity, while the distribution scale was 0; <10%, 1; 10%-40%, 2; 40%-70% and 3; >70%. A cut-off value for positivity was not used in their study (38). Anees et al. used the values of <10%, 10-30% and >30% for distribution of staining and the values of weak; 1, moderate; 2 and strong; 3 for staining intensity¹⁸. We have determined our own scoring system by modifying the scoring systems (Table II) and we have used a cut-off value in our study.

As can be inferred from the outcomes of our study, variations in the apoptotic process occur in benign and malignant lesions of the prostatic parenchyma. During carcinogenesis, genetic and molecular interactive changes are observed in the parenchymal and stromal cells of the prostate. Our results indicate that FasL expression by glandular cells occurs in the stage of HGPIN during prostate carcinogenesis. Decreased expression of Fas by stromal cells detected in our study opposes alterations facilitating anticipated tumoral invasion, while it might also represent a variation that might prolong the lifespan of the stromal cell so as to contribute to malignant transformation. However, FLIP expression in glandular cells suggests that anti-apoptotic effectiveness is gained during carcinogenesis. Another anti-apoptotic mechanism of resistance may be acquired by increased DcR1 expression observed with decreases in the degree of differentiation in cases with malignancies. Our outcomes indicate that anti-apoptotic mechanisms play important roles in prostate carcinogenesis.

CONFLICT of INTEREST
The authors declare no conflict of interest.

ACKNOWLEDGEMENT
This study was supported by Gaziosmanpaşa University Scientific Research Projects Committee (Project No: 2010/01).

1) Liu QY, Rubin MA, Omene C, Lederman S, Stein CA. Fas ligand is constitutively secreted by prostate cancer cells in vitro. Clin Cancer Res. 1998;4:1803-11.

2) Leithäuser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Möller P. Constitutive and induced expression of APO-1, a new member of the NGF/TNF receptor superfamily, in normal and neoplastic cells. Lab Invest. 1993;69:415-29.

3) Sasaki Y, Ahmed H, Takeuchi T, Moriyama N, Kawabe K. Immunohistochemical study of Fas, Fas ligand and interleukin-1 beta converting enzyme expression in human prostatic cancer. Br J Urol. 1998;81:852-5.

4) K im SY, Song SY, Kim MS, Lee JY, Lee HM, Choi HY, Yoo NJ, Lee SH. Immunohistochemical analysis of Fas and FLIP in prostate cancers. APMIS. 2009;117:28-33.

5) Jiang J, Ulbright TM, Zhang S, Eckert GJ, Kao C, Gardner TA, Koch MO, Eble JN, Cheng L. Fas and Fas ligand expression is elevated in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. Cancer. 2002;95:296-300.

6) K imura K, Gelmann EP. Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation. J Biol Chem. 2000;275:8610-7.

7) Munshi A, Pappas G, Honda T, McDonnell TJ, Younes A, Li Y, Meyn RE. TRA IL (APO-2L) induces apoptosis in human prostate cancer cells inhibitable by Bcl-2. Oncogene. 2001;20:3757-65.

8) Nimmanapalli R, Perkins CL, Orlando M, O’Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances Apo-2 ligand/ tumor necrosis factor-related apoptosisinducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001;61:759-63.

9) Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schröter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-5.

10) Mawji IA, Simpson CD, Hurren R, Gronda M, Williams MA, Filmus J, Jonkman J, Da Costa RS, Wilson BC, Thomas MP, Reed JC, Glinsky GV, Schimmer AD. Critical role for Fasassociated death domain-like interleukin-1-converting enzymelike inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst. 2007;99:811-22.

11) Santourlidis S, Warskulat U, Florl AR, Maas S, Pulte T, Fischer J, Müller W, Schulz WA. Hypermethylation of the tumor necrosis factor receptor superfamily 6 (APT1, Fas, CD95/Apo-1) gene promoter at rel/nuclear factor kB sites in prostatic carcinoma. Mol Carcinog. 2001;32:36-43.

12) Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB, Beer DG. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997;57:5571-8.

13) Nambu Y, Hughes SJ, Rehemtulla A, Hamstra D, Orringer MB, Beer DG. Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998;101:1102-10.

14) Higaki K, Yano H, Kojiro M. Fas antigen expression and its relationship with apoptosis in human hepatocellular carcinoma and noncancerous tissues. Am J Pathol. 1996;149:429-37.

15) Cunha GR, Hayward SW, Wang YZ, Ricke WA. Role of the stromal microenvironment in carcinogenesis of the prostate. Int J Cancer. 2003;107:1-10.

16) Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res. 2006;66:794-802.

17) Begley L, Keeney D, Beheshti B, Squire JA, Kant R, Chaib H, MacDonald JW, Rhim J, Macoska JA. Concordant copy number and transcriptional activity of genes mapping to derivative chromosomes 8 during cellular immortalization in vitro. Genes Chromosomes Cancer. 2006;45:136-46.

18) A nees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK. Recurrence-free survival in prostate cancer is related to increased stromal TRA IL expression. Cancer. 2011;117:1172-82.

19) Lee SH, Shin MS, Lee JY, Park WS, Kim SY, Jang JJ, Dong SM, Na EY , Kim CS, Kim SH, Yoo NJ. In vivo expression of soluble Fas and FAP-1: Possible mechanisms of Fas resistance in human hepatoblastomas. J Pathol. 1999;188:207-12.

20) Sato T, Irie S, Kitada S, Reed JC. FAP-1: A protein tyrosine phosphatase that associates with Fas. Science. 1995;268:411-5.

21) Thomas RK, Kallenborn A, Wickenhauser C, Schultze JL, Draube A, Vockerodt M, Re D, Diehl V, Wolf J. Constitutive expression of c-FLIP in Hodgkin and Reed-Sternberg cells. Am J Pathol. 2002;160:1521-8.

22) R yu BK, Lee MG, Chi SG, Kim YW, Park JH. Increased expression of cFLIP(L) in colonic adenocarcinoma. J Pathol. 2001;194:15-9.

23) Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRA IL induced apoptosis in human melanoma cells. J Immunol. 1998;161:2833-40.

24) Lee SH, Kim HS, Kim SY, Lee YS, Park WS, Kim SH, Lee JY, Yoo NJ. Increased expression of FLIP, an inhibitor of Fas-mediated apoptosis, in stomach cancer. APMIS. 2003;111:309-14.

25) Zhang X, Jin TG, Yang H, DeWolf WC, Khosravi-Far R, Olumi AF. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosisinducing ligand-mediated apoptosis in prostate cancer. Cancer Res. 2004;64:7086-91.

26) Shin MS, Park WS, Kim SY, Kim HS, Kang SJ, Song KY, Park JY, Dong SM, Pi JH, Oh RR, Lee JY, Yoo NJ, Lee SH. Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma. Am J Pathol. 1999;154:1785-91.

27) K im HS, Lee JW, Soung YH, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ, Jeong SW, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH. Inactivating mutations of caspase-8 gene in colorectal carcinomas. Gastroenterology. 2003;125:708-15.

28) Shin MS, Kim HS, Kang CS, Park WS, Kim SY, Lee SN, Lee JH, Park JY, Jang JJ, Kim CW, Kim SH, Lee JY, Yoo NJ, Lee SH. Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. Blood. 2002;99:4094-9.

29) Müllauer L, Mosberger I, Grusch M, Rudas M, Chott A. Fas ligand is expressed in normal breast epithelial cells and is frequently upregulated in breast cancer. J Pathol. 2000;190:20-30.

30) Hahne M, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini J, Tschopp J. Melanoma cell expression of Fas (Apo-1/CD95) ligand: Implications for tumor immune escape. Science. 1996;274:1363-

6)

31) A shkenazi A, Dixit VM. Death receptors: Signaling and modulation. Science. 1998;281:1305-8.

32) Griffith TS, Lynch DH. TRA IL: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol. 1998;10:559-63.

33) Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRA IL-induced apoptosis. J Biol Chem. 2001;276:10767-74.

34) Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A. Control of TRA ILinduced apoptosis by a family of signaling and decoy receptors. Science. 1997;277:818-21.

35) French LE, Tschopp J. The TRA IL to selective tumor death. Nat Med. 1999;5:146-7.

36) Sanlioglu AD, Koksal IT, Karacay B, Baykara M, Luleci G, Sanlioglu S. Adenovirus-mediated IKKbetaKA expression sensitizes prostate carcinoma cells to TRA IL-induced apoptosis. Cancer Gene Ther. 2006;13:21-31.

37) Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRA IL decoy receptor-4 expression is correlated with TRA IL resistance in MCF7 breast cancer cells. BMC Cancer. 2005;5:54.

38) Sanlioglu AD, Koksal IT, Ciftcioglu A, Baykara M, Luleci G, Sanlioglu S. Differential expression of TRA IL and its receptors in benign and malignant prostate tissues. J Urol. 2007;177:359-64.

39) Shankar S, Chen X, Srivastava RK. Effects of sequential treatments with hemotherapeutic drugs followed by TRA IL on prostate cancer in vitro and in vivo. Prostate. 2005;62:165-86.

40) Sridhar S, Ali AA, Liang Y, El Etreby MF, Lewis RW, Kumar MV. Differential expression of members of the tumor necrosis factor alpha-related apoptosis-inducing ligand pathway in prostate cancer cells. Cancer Res. 2001;61:7179-83.

41) Shankar S, Singh TR, Srivastava RK. Ionizing radiation enhances the therapeutic potential of TRA IL in prostate cancer in vitro and in vivo: Intracellular mechanisms. Prostate. 2004;61:35-49.

42) Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: Induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8:2912-23.

43) Dean JP, Nelson PS. Profiling influences of senescent and aged fibroblasts on prostate carcinogenesis. Br J Cancer. 2008;98:245-9.

44) Risbridger GP, Taylor RA . Minireview: Regulation of prostatic stem cells by stromal niche in health and disease. Endocrinology. 2008;149:4303-6.

45) Shimada K, Nakamura M, Matsuyoshi S, Ishida E, Konishi N. Specific positive and negative effects of FLIP on cell survival in human prostate cancer. Carcinogenesis. 2006;27:1349-57.